USO 22067
Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)
Disease Types: GYN Cancer Research
Eligibility Requirements:
- Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer, breast cancer (hormone receptor positive, HER2-negative and triple-negative), mesothelioma
- Previously received therapies known to confer clinical benefit
- Willing to provide a tumor sample (archive tissue or fresh biopsy)
- ECOG performance status 0 or 1
- Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline
- Adequate hematologic, hepatic, renal and cardiac function
- For Part B, evidence of folate receptor alpha expression in tumor cells
Available at: